Loading...
Loading...
INM| Name | Value |
|---|---|
| Revenues | 1,111.7M |
| Cost of Revenue | 650.8M |
| Gross Profit | 460.9M |
| Operating Expense | 2,613.9M |
| Operating I/L | -2,153.1M |
| Other Income/Expense | -422.0M |
| Interest Income | 0.0M |
| Pretax | -2,575.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -2,575.0M |
InMed Pharmaceuticals Inc. is a clinical stage pharmaceutical company specializing in cannabinoid-based therapies. Its lead product, INM-755, is a cannabinol topical cream undergoing Phase I clinical trials for treating epidermolysis bullosa. The company is also developing INM-088 for glaucoma and INM-405 for pain, with a focus on dermatology and ocular diseases. In addition, it conducts research on IND-enabling pharmacology and preclinical toxicology studies, and utilizes IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoid synthesis. InMed has a research collaboration agreement with BayMedica Inc. for novel cannabinoid therapeutics.
